Sponsors (28)
The bill improves privacy, independence, and safety for blind and low‑vision users of home medical devices but creates compliance and resource demands that could slow some product launches and raise costs for manufacturers, patients, and taxpayers.
People who are blind or have low vision gain private, independent access to home and personal medical device interfaces that provide nonvisual interaction comparable to sighted users.
Patients with chronic conditions and older adults can more safely and independently manage at‑home care because nonvisual interfaces reduce errors and provide multiple confirmation methods for readings and data.
Manufacturers and health systems get clearer regulatory timelines, training, and guidance to help comply with the accessibility requirements, reducing uncertainty about obligations.
Devices that cannot feasibly be modified may face delayed market entry if manufacturers need to redesign or pursue waivers, delaying access for patients who need them.
Additional design, testing, and compliance costs to meet new accessibility standards could raise device prices or impose costs on taxpayers and middle‑class families.
Requiring additional interface options and implementing new rules increases regulatory complexity and will require FDA staff time and resources for rulemaking, training, consultations, and waiver reviews, which could slow approvals and rollout.
Based on analysis of 3 sections of legislative text.
Requires FDA to set and enforce nonvisual accessibility standards for in‑home/patient-facing Class II and III medical device user interfaces, with rulemaking and waiver procedures.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish nonvisual accessibility standards for certain devices with digital interfaces, and for other purposes.
Introduced September 26, 2025 by Janice D. Schakowsky · Last progress September 26, 2025
Requires the FDA to set and enforce a nonvisual accessibility standard for certain Class II and III medical device user interfaces so blind and low-vision people can operate them with equivalent effectiveness and ease. It directs the FDA to propose regulations within 1 year, finalize them within 2 years, and make the final rule effective 1 year after publication; devices cleared or approved after that effective date must meet the standard or have an approved waiver.